The First Case of Gastric Neuroendocrine Tumors Induced by a Proton Pump Inhibitor in Von Hippel-Lindau Disease

Overview

Journal Intern Med

Specialty General Medicine

Date 2022 Feb 9

PMID 35135919

Authors

Koichiro Kawaguchi

Kazuo Yashima

Yuichiro Ikebuchi

Akira Yoshida

Satoshi Kuwamoto

Hajime Isomoto

Affiliations

Soon will be listed here.

Abstract

Von Hippel-Lindau (VHL) disease is a rare inherited familial syndrome complicated with various neoplasms, including neuroendocrine tumors (NETs). We herein report the first case of multiple gastric NETs in a 45-year-old man with VHL. He had multiple gastric polyps, and several endoscopic resected lesions were diagnosed as NETs. The serum gastrin level was elevated because he was taking a proton pump inhibitor (PPI). We suspected that gastrin had played a role in the development of NETs, and the remaining polyps were followed up with discontinuation of the PPI. The NETs gradually reduced in size until they became hard to notice on endoscopy and have remained nearly invisible for over eight years.

Citing Articles

When rare diseases crisscross within the same patient: von Hippel-Lindau and type 1 gastric neuroendocrine tumor.

Alexandraki K, Spyroglou A, Xekouki P, Bramis K, Kyriakopoulos G, Barkas K Hormones (Athens). 2024; 23(3):585-590.

PMID: 38619811 PMC: 11436398. DOI: 10.1007/s42000-024-00556-9.

Multiple Gastric Neuroendocrine Tumors Associated with Long-term Use of a Proton Pump Inhibitor and a Potassium-competitive Acid Blocker.

Nagao S, Yabuuchi Y, Tanaka K, Morihisa Y, Kobayashi T, Akiyama S Intern Med. 2023; 63(14):2001-2010.

PMID: 38008447 PMC: 11309866. DOI: 10.2169/internalmedicine.2857-23.

References

Kulke M, Mayer R . Carcinoid tumors. N Engl J Med. 1999; 340(11):858-68. DOI: 10.1056/NEJM199903183401107. View

Jianu C, Lange O, Viset T, Qvigstad G, Martinsen T, Fougner R . Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol. 2011; 47(1):64-7. DOI: 10.3109/00365521.2011.627444. View

Haga Y, Nakatsura T, Shibata Y, Sameshima H, Nakamura Y, Tanimura M . Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci. 1998; 43(2):253-7. DOI: 10.1023/a:1018881617038. View

Leung R, Biswas S, Duncan M, Rankin S . Imaging features of von Hippel-Lindau disease. Radiographics. 2008; 28(1):65-79. DOI: 10.1148/rg.281075052. View

Lonser R, Glenn G, Walther M, Chew E, Libutti S, Linehan W . von Hippel-Lindau disease. Lancet. 2003; 361(9374):2059-67. DOI: 10.1016/S0140-6736(03)13643-4. View

Speisky D, Duces A, Bieche I, Rebours V, Hammel P, Sauvanet A . Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients. Clin Cancer Res. 2012; 18(10):2838-49. DOI: 10.1158/1078-0432.CCR-11-2759. View

Itsuno M, Watanabe H, IWAFUCHI M, Ito S, Yanaihara N, Sato K . Multiple carcinoids and endocrine cell micronests in type A gastritis. Their morphology, histogenesis, and natural history. Cancer. 1989; 63(5):881-90. DOI: 10.1002/1097-0142(19890301)63:5<881::aid-cncr2820630515>3.0.co;2-k. View

Knebelmann B, Ananth S, Cohen H, Sukhatme V . Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 1998; 58(2):226-31. View

Ohh M, Park C, Ivan M, Hoffman M, Kim T, Huang L . Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000; 2(7):423-7. DOI: 10.1038/35017054. View

10.

Kim W, Kaelin W . Role of VHL gene mutation in human cancer. J Clin Oncol. 2004; 22(24):4991-5004. DOI: 10.1200/JCO.2004.05.061. View

11.

Williams G . Endocrine tumours of the gastrointestinal tract-selected topics. Histopathology. 2007; 50(1):30-41. DOI: 10.1111/j.1365-2559.2006.02570.x. View

12.

Modlin I, Tang L . The gastric enterochromaffin-like cell: an enigmatic cellular link. Gastroenterology. 1996; 111(3):783-810. DOI: 10.1053/gast.1996.v111.agast961110783. View

13.

Takahari K, Haruma K, Ohtani H, Kiyoto S, Watanabe A, Kamada T . Proton Pump Inhibitor Induction of Gastric Cobblestone-like Lesions in the Stomach. Intern Med. 2017; 56(20):2699-2703. PMC: 5675929. DOI: 10.2169/internalmedicine.7964-16. View

14.

Jianu C, Fossmark R, Viset T, Qvigstad G, Sordal O, Marvik R . Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther. 2012; 36(7):644-9. DOI: 10.1111/apt.12012. View

15.

Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas P . Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015; 42(6):649-63. DOI: 10.1111/apt.13324. View

16.

Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E . Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993; 104(4):994-1006. DOI: 10.1016/0016-5085(93)90266-f. View

17.

Nilsson O, Wangberg B, McRae A, Dahlstrom A, Ahlman H . Growth factors and carcinoid tumours. Acta Oncol. 1993; 32(2):115-24. DOI: 10.3109/02841869309083899. View

18.

Bordi C, DAdda T, Azzoni C, Ferraro G . Pathogenesis of ECL cell tumors in humans. Yale J Biol Med. 1999; 71(3-4):273-84. PMC: 2578995. View

19.

Miyamoto S, Kato M, Tsuda M, Matsuda K, Muranaka T, Abiko S . Gastric mucosal cracked and cobblestone-like changes resulting from proton pump inhibitor use. Dig Endosc. 2016; 29(3):307-313. DOI: 10.1111/den.12765. View

20.

Dawson R, Manson J . Omeprazole in oesophageal reflux disease. Lancet. 2000; 356(9243):1770-1. DOI: 10.1016/S0140-6736(05)71964-4. View